AU2007275415A1 - Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation - Google Patents
Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation Download PDFInfo
- Publication number
- AU2007275415A1 AU2007275415A1 AU2007275415A AU2007275415A AU2007275415A1 AU 2007275415 A1 AU2007275415 A1 AU 2007275415A1 AU 2007275415 A AU2007275415 A AU 2007275415A AU 2007275415 A AU2007275415 A AU 2007275415A AU 2007275415 A1 AU2007275415 A1 AU 2007275415A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- compound according
- moiety
- substituted
- aromatic ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80783706P | 2006-07-20 | 2006-07-20 | |
US60/807,837 | 2006-07-20 | ||
PCT/US2007/073656 WO2008011392A2 (fr) | 2006-07-20 | 2007-07-17 | Antagonistes ccr1 de proline urée utilisés pour des maladies auto-immunes et l'inflammation |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2007275415A1 true AU2007275415A1 (en) | 2008-01-24 |
AU2007275415A2 AU2007275415A2 (en) | 2009-03-12 |
Family
ID=38814356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007275415A Abandoned AU2007275415A1 (en) | 2006-07-20 | 2007-07-17 | Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2059502A2 (fr) |
JP (1) | JP2009544620A (fr) |
AU (1) | AU2007275415A1 (fr) |
IL (1) | IL196510A0 (fr) |
WO (1) | WO2008011392A2 (fr) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2742306A1 (fr) | 2008-11-03 | 2010-05-06 | Chemocentryx, Inc. | Composes pour le traitement de l'osteoporose et de cancers |
EP2771484A1 (fr) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | Nouveaux marqueurs d'infiltrat leucocytaire de rosacée et utilisations de ceux-ci |
KR102204989B1 (ko) * | 2012-01-12 | 2021-01-20 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
WO2013106646A2 (fr) * | 2012-01-12 | 2013-07-18 | Yale University | Composés et procédés pour l'inhibition de l'ubiquitine ligase vcb e3 |
ES2644700T3 (es) * | 2012-06-28 | 2017-11-30 | Novartis Ag | Derivados de pirrolidina y su uso como moduladores de la ruta del complemento |
WO2014002052A1 (fr) * | 2012-06-28 | 2014-01-03 | Novartis Ag | Dérivés pyrrolidine et leur utilisation en tant que modulateurs de la voie du complément |
JP6155332B2 (ja) * | 2012-06-28 | 2017-06-28 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
GB201414730D0 (en) * | 2014-08-19 | 2014-10-01 | Tpp Global Dev Ltd | Pharmaceutical compound |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
CN107428734A (zh) | 2015-01-20 | 2017-12-01 | 阿尔维纳斯股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
KR102616762B1 (ko) | 2015-03-18 | 2023-12-20 | 아비나스 오퍼레이션스, 인코포레이티드 | 타겟화된 단백질들의 향상된 분해를 위한 화합물들 및 방법들 |
WO2016197114A1 (fr) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs et procédés d'utilisation associés |
US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
CA3002709A1 (fr) | 2015-11-02 | 2017-05-11 | Yale University | Composes chimeres de ciblage de proteolyse et procedes de preparation et d'utilisation de ceux-ci |
US11084807B2 (en) | 2016-08-18 | 2021-08-10 | Vidac Pharama Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
ES2975558T3 (es) | 2016-09-15 | 2024-07-09 | Arvinas Inc | Derivados de indol como degradantes de receptor de estrógeno |
US10584101B2 (en) | 2016-10-11 | 2020-03-10 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
CN110234646A (zh) | 2016-11-01 | 2019-09-13 | 阿尔维纳斯股份有限公司 | 靶向PROTAC的Tau蛋白及相关使用方法 |
CN110291087B (zh) | 2016-12-01 | 2024-07-09 | 阿尔维纳斯运营股份有限公司 | 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物 |
US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
KR102564201B1 (ko) | 2016-12-23 | 2023-08-07 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
KR20190101406A (ko) | 2016-12-23 | 2019-08-30 | 아비나스 오퍼레이션스, 인코포레이티드 | Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법 |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
KR102582886B1 (ko) | 2017-01-26 | 2023-09-26 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법 |
US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
MX2020010420A (es) | 2018-04-04 | 2020-12-11 | Arvinas Operations Inc | Moduladores de la proteólisis y métodos asociados de uso. |
WO2020041331A1 (fr) | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Composé chimère ciblant la protéolyse (protac) ayant une activité de liaison à l'ubiquitine ligase e3 et ciblant une protéine alpha-synucléine pour le traitement de maladies neurodégénératives |
US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
BR112022012110A2 (pt) | 2019-12-19 | 2022-12-13 | Arvinas Operations Inc | Compostos e métodos para a degradação direcionada de receptor androgênico |
IL297762A (en) | 2020-05-09 | 2022-12-01 | Arvinas Operations Inc | Methods for producing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms including it |
CN111960991A (zh) * | 2020-07-23 | 2020-11-20 | 宿迁联盛科技股份有限公司 | 一种助剂及其制备方法 |
BR112023021265A2 (pt) | 2021-04-16 | 2024-02-27 | Arvinas Operations Inc | Moduladores da proteólise de bcl6 e métodos de uso associados |
WO2024054591A1 (fr) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Composés de dégradation de fibrosarcome rapidement accéléré (raf) et procédés d'utilisation associés |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001280187A1 (en) * | 2000-08-28 | 2002-03-13 | Toray Industries, Inc. | Cyclic amine derivatives |
EP1678121A4 (fr) * | 2003-10-24 | 2007-07-25 | Exelixis Inc | Modulateurs de kinases tao et leurs methodes d'utilisation |
EP1716134A4 (fr) * | 2004-02-12 | 2007-10-17 | Merck & Co Inc | Composes amino heterocycliques modulateurs de l'activite des recepteurs de chimiokines |
-
2007
- 2007-07-17 AU AU2007275415A patent/AU2007275415A1/en not_active Abandoned
- 2007-07-17 EP EP07799631A patent/EP2059502A2/fr not_active Withdrawn
- 2007-07-17 JP JP2009520949A patent/JP2009544620A/ja active Pending
- 2007-07-17 WO PCT/US2007/073656 patent/WO2008011392A2/fr active Application Filing
-
2009
- 2009-01-14 IL IL196510A patent/IL196510A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL196510A0 (en) | 2009-11-18 |
WO2008011392A3 (fr) | 2008-05-22 |
WO2008011392A8 (fr) | 2008-07-24 |
AU2007275415A2 (en) | 2009-03-12 |
WO2008011392A2 (fr) | 2008-01-24 |
JP2009544620A (ja) | 2009-12-17 |
EP2059502A2 (fr) | 2009-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007275415A1 (en) | Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation | |
RU2505539C2 (ru) | Антивирусные соединения | |
AU2010233952B2 (en) | Anthelmintic agents and their use | |
CA2807947C (fr) | Derive de triazine et composition pharmaceutique presentant une activite analgesique a teneur en derive de triazine | |
EP0690851B1 (fr) | Derives de guanidine efficaces en therapeutique | |
AU2006297089A1 (en) | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | |
US8288371B2 (en) | Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation | |
NZ233252A (en) | Thiourea and guanidine derivatives and pharmaceutical compositions | |
JP4268871B2 (ja) | ピリミジノン化合物及びその薬剤として許容される塩の製造方法 | |
AU2021209727A1 (en) | Isoindoline derivative, and pharmaceutical composition and use thereof | |
US8168634B2 (en) | Thiazole derivatives as kinase inhibitors | |
AU2004293012A1 (en) | Quinazolinone compounds with reduced bioaccumulation | |
CA3188350A1 (fr) | Procedes de fabrication de composes tricycliques serd ayant un fragment phenyle ou pyridinyle substitue | |
OA12293A (en) | 3-Azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity. | |
JP2016522240A (ja) | RORcモジュレーターとしてのアリールスルタム誘導体 | |
CZ20023192A3 (cs) | Antagonisté IL-8 receptoru | |
US9938272B2 (en) | Hydrazine compound as blood coagulation factor Xa inhibitor | |
US20030105073A1 (en) | Quinolone derivatives | |
US4731369A (en) | Amides and esters of 2-(N-(hydroxypiperidinoalkyl) and (hydroxypyrrolidinoalkyl)-aminosulfonyl)-6-nitrobenzoic acids useful as adjuncts to radiation therapy | |
WO1999029672A1 (fr) | AGONISTES β3-ADRENERGIQUES SPECIFIQUES | |
CA2490148A1 (fr) | Derives de pyrimidine a substitution 2, 5 utilises en tant qu'antagonistes ix du recepteur ccr-3 | |
CA2287394A1 (fr) | Methodes de synthese d'imidazoles 2-substitues | |
EP0223124B1 (fr) | Esters ou amides aminosulfonyl-6-nitrobenzoiques substitués, leurs procédés de fabrication et compositions pharmaceutiques les contenant | |
AU2005229666A1 (en) | Nitrogen-containing 5-membered ring compound | |
TW202412782A (zh) | 用於治療trpm3介導之病症的吲唑衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 FEB 2009 |
|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |